Fukuoka, Kurume, Japan Clinical Trials

A listing of Fukuoka, Kurume, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 68 clinical trials
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) …

alpha fetoprotein
ct scan
pembrolizumab
hepatitis
Kurume University Hospital ( Site 0119)
 (0.6 away) Contact site
  • 136 views
  • 29 Jul, 2021
  • +254 other locations
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

mirikizumab
plaque psoriasis
Kurume University Hospital
 (0.6 away) Contact site
  • 717 views
  • 27 Jul, 2021
  • +354 other locations
Study of Durvalumab + Tremelimumab Durvalumab and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

limited stage small cell lung cancer
cancer chemotherapy
chemoradiotherapy
prophylactic cranial irradiation
etoposide
Research Site
 (0.6 away) Contact site
  • 268 views
  • 01 Aug, 2021
  • +246 other locations
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

mirikizumab
Yukinoseibokai St. Mary's Hospital
 (1.0 away) Contact site
  • 1722 views
  • 24 Jul, 2021
  • +880 other locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

acute coronary syndrome
arterial disease
myocardial infarction
stroke
stemi
3920110 - Kurume University Hospital
 (0.6 away) Contact site
  • 1118 views
  • 01 Aug, 2021
  • +3430 other locations
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Kurume University Hospital
 (0.6 away) Contact site
  • 40 views
  • 28 Jun, 2021
  • +121 other locations
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or IIA non-small cell lung cancer (NSCLC). The primary study hypotheses are: SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared …

pembrolizumab
mk-3475
stereotactic body radiation therapy
lung carcinoma
Kurume University Hospital ( Site 2815)
 (0.6 away) Contact site
  • 121 views
  • 01 Aug, 2021
  • +178 other locations
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 compared with placebo, in Non-alcoholic Steatohepatitis (NASH) participants with Stage 2, Stage 3 liver fibrosis. This study is designed to assess response to treatment on measures of fibrosis and …

fatty liver
liver disease
steatohepatitis
hepatic fibrosis
fibrosis
Kurume University Hospital
 (0.6 away) Contact site
  • 452 views
  • 20 Jun, 2021
  • +132 other locations
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

The main purpose of this study is to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

epidermal growth factor
epidermal growth factor receptor
chemoradiotherapy
durvalumab
stage iii non-small cell lung cancer
Kurume University Hospital - Dept of Lung Cancer Center
 (0.6 away) Contact site
  • 28 views
  • 28 Jan, 2021
  • +104 other locations
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC MK-7339-008/KEYLYNK-008)

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival (PFS) per RECIST 1.1 by …

Kurume University Hospital ( Site 0814)
 (0.6 away) Contact site
  • 119 views
  • 01 Aug, 2021
  • +202 other locations